标题
Inclisiran in lipid management: A Literature overview and future perspectives
作者
关键词
Inclisiran, SiRNAs, Lipid management, LDL-C
出版物
BIOMEDICINE & PHARMACOTHERAPY
Volume 143, Issue -, Pages 112227
出版商
Elsevier BV
发表日期
2021-09-24
DOI
10.1016/j.biopha.2021.112227
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- The growth of siRNA-based therapeutics: updated clinical studies
- (2021) M. May Zhang et al. BIOCHEMICAL PHARMACOLOGY
- New Insight Into Metformin-Induced Cholesterol-Lowering Effect Crosstalk Between Glucose and Cholesterol Homeostasis via ChREBP (Carbohydrate-Responsive Element-Binding Protein)-Mediated PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Regulation
- (2021) Die Hu et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Inclisiran: First Approval
- (2021) Yvette N. Lamb DRUGS
- Clinical impact and room for improvement of intensity and adherence to lipid lowering therapy: Five years of clinical follow-up from 164,565 post-myocardial infarction patients
- (2021) François Schiele et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)
- (2021) Maciej Banach et al. PHARMACOLOGICAL RESEARCH
- Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
- (2020) Jan Borén et al. EUROPEAN HEART JOURNAL
- Low Adherence to Statin Treatment during the First Year after an Acute Myocardial Infarction is associated with Increased Second Year Mortality Risk— An Inverse Probability of Treatment Weighted Study on 54,872 Patients
- (2020) Kani Khalaf et al. European Heart Journal-Cardiovascular Pharmacotherapy
- A Meta-Analysis of Cardiovascular Outcomes in Patients With Hypercholesterolemia Treated With Inclisiran
- (2020) Abdul Aziz A. Asbeutah et al. AMERICAN JOURNAL OF CARDIOLOGY
- Insights from ORION studies: focus on inclisiran safety
- (2020) Alberico L Catapano et al. CARDIOVASCULAR RESEARCH
- Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia
- (2020) G. Kees Hovingh et al. CIRCULATION
- Cardiovascular Corner—Stable Coronary Artery Disease, An LDL “Vaccine,” and Anti-inflammatories
- (2020) Jennifer Abbasi JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
- (2020) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
- (2020) Frederick J. Raal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Quantitative evaluation of statin effectiveness versus intolerance and strategies for management of intolerance
- (2020) Handrean Soran et al. ATHEROSCLEROSIS
- Lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment after acute coronary syndrome: a Danish population-based cohort study
- (2020) Marie Skov Kristensen et al. BMC Cardiovascular Disorders
- Have we learnt all from IMPROVE-IT? Part II. Subanalyses on the ef- fects of ezetimibe added to statin therapy on selected clinical and laborato- ry outcomes, cost effectiveness, guideline and clinical implications
- (2020) Zlatko Fras et al. Current Vascular Pharmacology
- Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets
- (2020) Lluís Masana et al. Current Cardiology Reports
- PCSK9 and atherosclerosis: Looking beyond LDL regulation
- (2020) Rosetta Ragusa et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease
- (2019) Shuaib M. Abdullah et al. CIRCULATION
- Treating Disease at the RNA Level with Oligonucleotides
- (2019) Arthur A. Levin NEW ENGLAND JOURNAL OF MEDICINE
- Adherence to Statin Therapy Among US Adults Between 2007 and 2014
- (2019) Lisandro D. Colantonio et al. Journal of the American Heart Association
- Relative Effect of Current Intensive Lipid-Lowering Drugs on Cardiovascular Outcomes in Secondary Prevention ― A Meta-Analysis of 12 Randomized Trials ―
- (2019) Shifei Wang et al. CIRCULATION JOURNAL
- Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries
- (2019) Guy De Backer et al. ATHEROSCLEROSIS
- Associations of Blood Pressure and Cholesterol Levels During Young Adulthood With Later Cardiovascular Events
- (2019) Yiyi Zhang et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- A NEW DAWN FOR MANAGING DYSLIPIDEMIAS: THE ERA OF RNA-BASED THERAPIES
- (2019) C. Macchi et al. PHARMACOLOGICAL RESEARCH
- Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels
- (2019) Kausik K. Ray et al. JAMA Cardiology
- Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9
- (2019) Charles A. German et al. BIODRUGS
- Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies
- (2019) R. Scott Wright et al. MAYO CLINIC PROCEEDINGS
- Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants
- (2019) Nelson Wang et al. Lancet Diabetes & Endocrinology
- Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering
- (2018) Eliano P. Navarese et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characteristics of lipid profile and effectiveness of management of dyslipidaemia in patients with acute coronary syndromes – Data from the TERCET registry with 19,287 patients
- (2018) Krzysztof Dyrbus et al. PHARMACOLOGICAL RESEARCH
- Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials
- (2017) Konstantinos C Koskinas et al. EUROPEAN HEART JOURNAL
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oligonucleotide Therapeutics — A New Class of Cholesterol-Lowering Drugs
- (2017) Anastasia Khvorova NEW ENGLAND JOURNAL OF MEDICINE
- A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
- (2017) Kevin Fitzgerald et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
- (2017) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Well-Defined Multivalent Ligands for Hepatocytes Targeting via Asialoglycoprotein Receptor
- (2016) Xiangang Huang et al. BIOCONJUGATE CHEMISTRY
- 2016 European Guidelines on cardiovascular disease prevention in clinical practice
- (2016) Massimo F. Piepoli et al. EUROPEAN HEART JOURNAL
- Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials
- (2015) A. Sahebkar et al. DIABETES OBESITY & METABOLISM
- Asialoglycoprotein receptor mediated hepatocyte targeting — Strategies and applications
- (2015) Anisha A. D'Souza et al. JOURNAL OF CONTROLLED RELEASE
- Hepatic Overexpression of Idol Increases Circulating Protein Convertase Subtilisin/Kexin Type 9 in Mice and Hamsters via Dual Mechanisms
- (2014) Makoto Sasaki et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- PCSK9 gene mutations and low-density lipoprotein cholesterol
- (2014) Na-Qiong Wu et al. CLINICA CHIMICA ACTA
- Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration
- (2014) Sam Chen et al. JOURNAL OF CONTROLLED RELEASE
- Physiological Roles of Asialoglycoprotein Receptors (ASGPRs) Variants and Recent Advances in Hepatic-Targeted Delivery of Therapeutic Molecules Via ASGPRs
- (2014) Jing Hu et al. PROTEIN AND PEPTIDE LETTERS
- The Multifaceted Proprotein Convertases: Their Unique, Redundant, Complementary, and Opposite Functions
- (2013) Nabil G. Seidah et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and Atherosclerosis
- (2013) Daniel Urban et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
- (2013) Kevin Fitzgerald et al. LANCET
- Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations
- (2013) Janice Mayne et al. Lipids in Health and Disease
- The biology and therapeutic targeting of the proprotein convertases
- (2012) Nabil G. Seidah et al. NATURE REVIEWS DRUG DISCOVERY
- Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
- (2012) Evan A. Stein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes
- (2011) John R Guyton et al. Diabetes & Vascular Disease Research
- Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol
- (2011) Judith Hsia et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The activation and physiological functions of the proprotein convertases
- (2008) N SEIDAH et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Newly identified loci that influence lipid concentrations and risk of coronary artery disease
- (2008) Cristen J Willer et al. NATURE GENETICS
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
- (2008) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
- (2008) M. Frank-Kamenetsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search